Aim of the present prospective study was to assess the potential benefits of complementary
insulin therapy, consisting of a single dose of 1 to 8 units of shortacting insulin
before each meal, on blood glucose, serum lipid parameters and on patient's well-being.
A group of 251 type 2 (non-insulin-dependent) diabetic patients completed the study.
The complementary insulin therapy was introduced in hospital in the course of one
week. Number of injections per day was increased, the average dose of insulin per
day and the average dose of glibenclamide decreased, amount of carbohydrates in food
(adapted by patients themselves) diminished, mean blood glucose, number of hyperglycaemia's
and number of hypoglycaemia's decreased. At a check-up 8 to 10 weeks later, a decrease
of haemoglobin A 1c, glycated proteins in serum and body mass index together with
improved patient's well-being have been shown. These results demonstrate a good effectiveness
of complementary insulin therapy in type 2 (non-insulin-dependent) diabetic patients.
We assume this kind of therapy should be more often recommended.
Supported by grants MZ CR IGA 0715-3 and IGA 1617-3).
type 2 (non-insulin-dependent) diabetes mellitus - complementary insulin therapy -
liberalized diet - glibenclamide - blood glucose
